Early Breast Cancer (ER-positive, HER2-negative)
ER-positive, HER2-negative early breast cancer is a type of breast cancer that grows in response to estrogen but does not have excess HER2 protein. This subtype is often treated with hormone therapy.
Early Breast Cancer: Abemaciclib and Giredestrant Study
We are investigating the safety and effectiveness of two medications for patients with early-stage, hormone-sensitive breast cancer before surgery. The goal is to see if this treatment can help reduce tumor size and improve outcomes.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you a woman aged 18 years or older?
- Do you have breast cancer that is eligible for primary surgery?
- Have you had any previous treatment for breast cancer, such as chemotherapy, hormone therapy, or surgery?
- Are you currently pregnant or breastfeeding?
- Do you have any serious health conditions that your doctor has told you about, like severe heart or liver problems?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Ro7197597
Giredestrant
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Centro Di Riferimento Oncologico Di Aviano
SOC Oncologia Medica e Prevenzione Oncologica
Aviano-Castello, Italy
IRCCS Ospedale Policlinico San Martino
Clinica di Oncologia Medica
Genoa, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
UOC Oncologia Medica
La Massimina-Casal Lumbroso, Italy
Sponsor: Fondazione Oncotech Impresa Sociale
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.